NCT04741906

Brief Summary

Aim of the study is to examine the feasibility of dental implant insertion in patients receiving high, adjuvant and low dose \> 4 years.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
225

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2017

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2017

Completed
3.5 years until next milestone

First Submitted

Initial submission to the registry

January 21, 2021

Completed
15 days until next milestone

First Posted

Study publicly available on registry

February 5, 2021

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

August 21, 2024

Status Verified

August 1, 2024

Enrollment Period

8.4 years

First QC Date

January 21, 2021

Last Update Submit

August 20, 2024

Conditions

Keywords

Dental implantsHigh dose antiresorptive medicationRehabilitationDenosumabBisphosphonateOral rehabilitationAdjuvant dose antiresorptive medicationLow dose antiresorptive medicationBone modifying agents

Outcome Measures

Primary Outcomes (6)

  • Dental implant survival

    Defined as presence of the implant in the jaw after initial implant surgery before abutment surgery

    3 months

  • Dental implant survival

    Defined as presence of the implant at time of final prosthetics

    6 months

  • Dental implant survival

    Defined as presence of the implant 1 year after loading of the final prosthetics

    18 months

  • Dental implant survival

    Defined as presence of the implant 2 years after loading of the final prosthetics

    30 months

  • Dental Implant success

    Defined as less marginal bone loss than 1.5 mm the first year, and 0.2 mm per year thereafter at time of assessment

    30 months

  • Absence of medical related osteonecrosis of the jaw (MRONJ)

    Defined as no exposed bone, no fistula, no radiologic sign of MRONJ

    30 months

Secondary Outcomes (2)

  • Oral Health Impact Profile

    30 months

  • EORTC QLQ-H&N 35

    30 months

Study Arms (9)

Patient with osteoporosis - antiresorptive treatment > 4 years. Previous tooth extraction

Patient with osteoporosis - antiresorptive treatment \> 4 years who have had previous tooth extraction without development of MRONJ

Procedure: Dental implant surgeryProcedure: Prosthetic treatment

Patient with osteoporosis - antiresorptive treatment > 4 years. Previous resection

Patient with osteoporosis - antiresorptive treatment \> 4 years who have lost teeth due to having previous osteonecrosis of the jaw which has been successfully surgically treated and healed for at least 3 months without recurrence

Procedure: Dental implant surgeryProcedure: Prosthetic treatment

Patient with osteoporosis - antiresorptive treatment > 4 years. Simultaneously with resection

Patient with osteoporosis - antiresorptive treatment \> 4 years with ongoing osteonecrosis of the jaw to be surgically treated with block resection of the lower jaw and insertion of a titanium reconstruction plate. Simultaneous insertion of dental implants, or resection of the upper jaw where there is sufficient remaining bone volume to have implants inserted simultaneously (without bone augmentation)

Procedure: Dental implant surgeryProcedure: Prosthetic treatment

Patient with cancer - adjuvant dose antiresorptive treatment. Previous tooth extraction

Patient with cancer (breast, prostate or multiple myeloma) - adjuvant dose antiresorptive treatment who have had previous tooth extraction without development of MRONJ

Procedure: Dental implant surgeryProcedure: Prosthetic treatment

Patient with cancer - adjuvant dose antiresorptive treatment. Previous resection

Patient with cancer (breast, prostate or multiple myeloma) - adjuvant dose antiresorptive treatment who have lost teeth due to having previous osteonecrosis of the jaw which has been successfully surgically treated and healed for at least 3 months without recurrence

Procedure: Dental implant surgeryProcedure: Prosthetic treatment

Patient with cancer - adjuvant dose antiresorptive treatment. Simultaneously with resection

Patient with cancer (breast, prostate or multiple myeloma) - adjuvant dose antiresorptive treatment with ongoing osteonecrosis of the jaw to be surgically treated with block resection of the lower jaw and insertion of a titanium reconstruction plate. Simultaneous insertion of dental implants, or resection of the upper jaw where there is sufficient remaining bone volume to have implants inserted simultaneously (without bone augmentation)

Procedure: Dental implant surgeryProcedure: Prosthetic treatment

Cancer patient treated with high dose antiresorptive treatment. Previous tooth extraction

Cancer patient treated with high dose antiresorptive treatment who have had previous tooth extraction without development of MRONJ

Procedure: Dental implant surgeryProcedure: Prosthetic treatment

Cancer patient treated with high dose antiresorptive treatment. Previous resection

Cancer patient treated with high dose antiresorptive treatment who have lost teeth due to having previous osteonecrosis of the jaw which has been successfully surgically treated and healed for at least 3 months without recurrence

Procedure: Dental implant surgeryProcedure: Prosthetic treatment

Cancer patient treated with high dose antiresorptive treatment. Simultaneously with resection

Cancer patients (breast, prostate or multiple myeloma) treated with high dose antiresorptive treatment with ongoing osteonecrosis of the jaw to be surgically treated with block resection of the lower jaw and insertion of a titanium reconstruction plate. Simultaneous insertion of dental implants, or resection of the upper jaw where there is sufficient remaining bone volume to have implants inserted simultaneously (without bone augmentation)

Procedure: Dental implant surgeryProcedure: Prosthetic treatment

Interventions

Dental surgery in patients treated with antiresorptive medication

Cancer patient treated with high dose antiresorptive treatment. Previous resectionCancer patient treated with high dose antiresorptive treatment. Previous tooth extractionCancer patient treated with high dose antiresorptive treatment. Simultaneously with resectionPatient with cancer - adjuvant dose antiresorptive treatment. Previous resectionPatient with cancer - adjuvant dose antiresorptive treatment. Previous tooth extractionPatient with cancer - adjuvant dose antiresorptive treatment. Simultaneously with resectionPatient with osteoporosis - antiresorptive treatment > 4 years. Previous resectionPatient with osteoporosis - antiresorptive treatment > 4 years. Previous tooth extractionPatient with osteoporosis - antiresorptive treatment > 4 years. Simultaneously with resection

Prosthetic treatment and loading of the dental implants

Cancer patient treated with high dose antiresorptive treatment. Previous resectionCancer patient treated with high dose antiresorptive treatment. Previous tooth extractionCancer patient treated with high dose antiresorptive treatment. Simultaneously with resectionPatient with cancer - adjuvant dose antiresorptive treatment. Previous resectionPatient with cancer - adjuvant dose antiresorptive treatment. Previous tooth extractionPatient with cancer - adjuvant dose antiresorptive treatment. Simultaneously with resectionPatient with osteoporosis - antiresorptive treatment > 4 years. Previous resectionPatient with osteoporosis - antiresorptive treatment > 4 years. Previous tooth extractionPatient with osteoporosis - antiresorptive treatment > 4 years. Simultaneously with resection

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Total or partial toothless patients treated with antiresorptive medication, treated at Copenhagen University Hospital due to treatment with high dose, adjuvant, or low dose \> 4 years, antiresorptive treatment. The patients had former tooth extractions or resections of the jaw at our clinic.

You may qualify if:

  • Patient with cancer or osteoporosis, treated with antiresorptive treatment.
  • The patients should have sufficient compliance, this includes willingness to have the planned assessments
  • The patient should have an expected life span at enrollment of at least 2 years.
  • The local bone quality and quantity should be sufficient for implant insertion without bone augmentation and is classified according to the classification by Cawood \& Howell 1988.

You may not qualify if:

  • \> 10 cigarettes daily
  • HbA1c \> 53 mmol/mol
  • Poor oral hygiene
  • Poor general condition: ECOG score 3 or 4.
  • Presence of metastases of the liver brain.
  • Poor local jaw bone quality acc. to Cawood classification stage 3 or 4.
  • Unwillingness to comply with the planned assessments and recordings

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Copenhagen University Hospital, Maxillofacial Department

Copenhagen, Danmark, 2300, Denmark

RECRUITING

Related Publications (2)

  • Ottesen C, Andersen SWM, Jensen SS, Kofod T, Gotfredsen K. Medication-related osteonecrosis of the jaw and successful implant treatment in a patient on high-dose antiresorptive medication: A case report. Clin Exp Dent Res. 2022 Oct;8(5):1059-1067. doi: 10.1002/cre2.620. Epub 2022 Jul 27.

  • Andersen SWM, Ottesen C, Gotfredsen K, Jensen SS, Kofod T, Schiodt M. Outcome of healing after dental implant placement in patients with cancer on high-dose antiresorptive medications: a prospective feasibility study. Oral Maxillofac Surg. 2023 Mar;27(1):89-100. doi: 10.1007/s10006-022-01042-5. Epub 2022 Jan 27.

MeSH Terms

Conditions

AnodontiaNeoplasmsOsteoporosis

Condition Hierarchy (Ancestors)

Tooth AbnormalitiesStomatognathic System AbnormalitiesStomatognathic DiseasesTooth DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesBone Diseases, MetabolicBone DiseasesMusculoskeletal DiseasesMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Sanne Werner Moeller Andersen, DDS

    Copenhagen University Hospital, Maxillofacial surgery

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Sanne Werner Moeller Andersen, DDS

CONTACT

Thomas Kofod, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
2 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Oral and Maxillofacial Surgeon

Study Record Dates

First Submitted

January 21, 2021

First Posted

February 5, 2021

Study Start

August 1, 2017

Primary Completion

December 31, 2025

Study Completion

December 31, 2025

Last Updated

August 21, 2024

Record last verified: 2024-08

Locations